30 results about "Plasma mhpg" patented technology

The utility model discloses a device for preparing platelet-rich plasma suspension and gel containing blood cells. Comprising a fixing frame, at least one rapid clamping pipe clamp installed on the fixing frame, a vacuum centrifugal pipe clamped in the rapid clamping pipe clamp, and two suction devices capable of being inserted into the centrifugal pipe from the top or the bottom of the centrifugal pipe. The pusher is used for pushing the aspirator to be inserted into the centrifugal tube; the rotating mechanism is used for driving the pusher to rotate so as to enable the aspirator to face the top or the bottom of the centrifugal tube; the utility model solves the problems of blood pollution, manual operation error and low extraction rate in the manual operation process in the prior art, retains all blood platelets and white blood cells in the blood, retains red blood cells in normal proportion and most plasma proteins, and improves the extraction efficiency. Moreover, the concentration of platelets and leukocytes is constantly about 4 times of the concentration of blood of common normal people, the functions of erythrocyte components are reserved, and the functional effects of various components in the blood can be better exerted.

The invention relates to a blood shearing device and a blood compatibility evaluation method. The blood shearing device comprises an objective table, a fixing support, a supporting beam, a stator, a rotor and a driving source. The device can simultaneously adjust the roughness and wettability of the material surface, breaks through the limitation that only a single factor can be researched in the prior art, and provides a more comprehensive platform for systematically evaluating the blood compatibility; in the experimental method, red blood cell hemolysis is detected, and the degradation condition of plasma protein is evaluated synchronously, so that the overall injury mode of blood components under the action of an artificial surface can be reflected more truly. Experimental basis can be provided for material selection and surface optimization of blood contact type medical instruments such as an artificial heart pump, an ECMO and a hemodialysis machine, the clinical complication risk can be reduced, and development of artificial organs and blood purification technologies is promoted.

The present application relates to the field of medical informatics, and provide a paliperidone efficacy prediction method and system based on plasma proteomics, the method comprises the following steps: collecting the basic data of the target patient; selecting the protein features through the basic data to obtain the related proteins corresponding to the paliperidone efficacy; training the neural network based on the related proteins and the baseline data in the basic data to obtain the prediction model; predicting the paliperidone efficacy of the patient to be predicted through the prediction model to obtain the prediction result. The present application can predict the treatment response of schizophrenic patients to paliperidone, and significantly improve the objectivity of paliperidone use.

This invention discloses a plasma protein as a biomarker for diagnosing NSTEMI complicated with hypertension and its application. The characteristic is that the plasma protein biomarker is MYL3, which can be used in the preparation of products for diagnosing NSTEMI complicated with hypertension. The advantage is that it can diagnose NSTEMI complicated with hypertension at an early stage by measuring the plasma protein biomarker, providing an effective tool for the diagnosis of NSTEMI complicated with hypertension, with high detection efficiency and strong targeting.

The application discloses an axSpA diagnosis biomarker combination and application thereof in judging axSpA diagnosis effect, relates to the biomedical field, and comprises the following four plasma proteins: LIM and SH3 domain protein 1 (LASP1), calponin binding protein 2 (CNN2), neuron protein kinase C and tyrosine protein kinase substrate 2 (PACSIN2) and tropomyosin 4 (TPM4). The expression levels of the four proteins in the plasma of axSpA light / severe group patients are all up-regulated relative to a healthy control group, and there is a significant difference between the severe group and the light group. Through deep proteomics, multi-algorithm statistics, machine learning models and independent queue immunological verification, the protein combination composed of LASP1, CNN2, PACSIN2 and TPM4 is first systematically identified and verified as an excellent performance of axSpA diagnosis biomarker.

The present invention relates to a therapeutic composition from natural substances that targets cancer cells, specifically brain cancer cells, and to a method for preparing same, wherein the composition comprises: 1) a therapeutic agent extracted from black seed, in the form of thymoquinone and 2) between 238,671 and 1,500,000,000 platelets, wherein components (a) and (b) are dissolved in 1 mL blood plasma proteins.

The invention belongs to the technical field of biological detection, and particularly relates to application of annexin A3 (ANXA3) in detection of critical illness death early warning and sepsis diagnosis. It is found that the ANXA3 protein amount in plasma of a critically ill patient is remarkably higher than that in a healthy voluntary person, the ANXA3 protein amount in plasma of a critically ill sepsis patient is remarkably higher than that in plasma of a critically ill non-sepsis patient, and the ANXA3 protein amount in the plasma is further remarkably related to the death risk of the critically ill patient. By detecting the blood plasma ANXA3 protein amount, sepsis occurrence and death risks of critically ill patients can be evaluated, individualized treatment can be started as soon as possible, and the kit has important clinical application value for prognosis of critically ill patients.

The invention discloses a biomarker for aortic dissection detection and an application of the biomarker. The biomarker is one or more of MDK, NTN1, CCL21, LIPC, DNASE1L3, TFPI2, CTSG, HAMP, CXCL14, PLA2G2A, SCUBE1, GZMK, HP1BP3, SRP14 and TOP1. The biomarker is obtained by screening plasma of a patient with aortic dissection through plasma proteomics, and shows relatively high sensitivity and specificity. ELISA verification proves that the biomarker can be used as an early diagnostic biomarker of the aortic dissection, and can also be used as one of indexes for evaluating the disease severity of AD patients, so that a new direction is provided for clinical early diagnosis and long-term prognosis evaluation of the aortic dissection.

The invention provides a system for predicting the level of pulmonary artery systolic pressure after sudden plateau entry, and the system obtains the plasma protein marker content, nicotinamide phosphoribosyltransferase, HECT structural domain E3 ubiquitin protein ligase 3 and heat shock protein family A member 1A of a testee in a plain area to predict the level of pulmonary artery systolic pressure 7 days after sudden plateau entry. And acquiring the plasma protein marker content and synaptic binding protein II of the testee 7 days after the testee rapidly enters the plateau to predict the pulmonary artery systolic pressure level 1 year after entering the plateau. The method can predict the pulmonary artery systolic pressure grade of the subject after the subject enters the plateau or enters the plateau for one year according to the plasma protein marker content of the subject, and is used for screening susceptible people in an early stage.

This invention relates to bifunctional compounds and the use of such bifunctional compounds to reduce plasma levels of extracellular target molecules via lysosomal degradation. These bifunctional compounds have cell surface receptor ligands covalently linked to ligands capable of binding to extracellular target molecules (such as growth factors, cytokines, chemokines, hormones, neurotransmitters, capsids, soluble receptors, extracellular secretory proteins, antibodies, lipoproteins, exosomes, viruses, cell or plasma membrane proteins), wherein said cell surface receptors are associated with receptor-mediated endocytosis, including lysosomal degradation mediated by desialylate glycoprotein receptor (ASGPR) and lysosomal degradation mediated by mannose-6-phosphate receptor (M6PR). Pharmaceutical compositions comprising such bifunctional compounds and methods of treating diseases or disorders mediated by extracellular molecules using such bifunctional compounds are also provided herein.

This application relates to the field of medical testing technology, specifically to a biomarker, diagnostic method, and application for the diagnosis of liver fibrosis. Through plasma proteomics analysis of patients with liver fibrosis, this application has discovered and validated a series of biomarkers and combinations thereof with clinical value for the early diagnosis of liver fibrosis.

The present application belongs to the technical field of blood product preparation, and particularly relates to a method for separating blood coagulation factor VIII and vWF factor from blood plasma. The method comprises the following steps in sequence: after cellulose is balanced, the cellulose is mixed with raw material blood plasma, filtered after stirring, and cellulose precipitate is obtained; after the cellulose precipitate is eluted, the cellulose precipitate is soaked in precipitate dissolving solution, and filtrate is obtained by filtering; the filtrate is subjected to three times of ion exchange chromatography, and factor VIII and / or vWF factor product is obtained. The technical scheme solves the technical problems of the prior art, such as complicated process steps for purifying and enriching human blood coagulation factor VIII and vWF from blood plasma cold precipitate, and unsatisfactory production efficiency and product quality. The cold precipitate protein solution prepared by the method can separate factor VIII, vWF factor and fibrinogen product at the same time through chromatography, improve the utilization rate of plasma protein, and has an ideal application prospect.

The application discloses a method for determining the bismuth plasma protein binding rate of bismuth potassium citrate, and is characterized in that the method comprises plasma sample pretreatment and sample determination. The determination method can solve the stability problem of bismuth potassium citrate in plasma, can make protein binding more sufficient, can effectively promote the dissociation of bismuth and plasma protein, can make the detected protein binding rate closer to the real value, has great significance for guiding clinical medication, is simple and easy to operate, can realize rapid detection, and has low dependence on instruments.

The invention discloses a method for constructing a model for accurately predicting meningeal metastasis risk of non-small cell lung cancer based on plasma protein and application, and relates to the technical field of biological medicine. Aiming at the problems of late discovery and difficult diagnosis of NSCLC-LM, the inventor tries to adopt an Olink proteomics technology for the first time to know whether an LM risk exists or not in advance by detecting specific plasma protein of a patient in a relatively non-invasive manner, so that the patient is helped to find and treat early. Therefore, the inventor firstly collects blood samples of LM and nLM patients, then constructs a risk prediction model by using a training set, and finally judges the efficiency of the model through a verification set. A result shows that five specific proteins, namely FGF2, CD4, IL15, CXCL12 and PDCD1LG2, participate in model construction, the area under a queue curve is 0.8 or above, and the sensitivity and the specificity both reach relatively high levels. The invention has great significance in the fields of early diagnosis and screening of NSCLC-LM and the like.

The invention belongs to the technical field of plasma protein markers, and discloses a plasma protein marker and a risk prediction system for a heart failure onset risk of a type 2 diabetes mellitus patient, and the protein marker combination is applied to preparation of a kit for predicting the heart failure onset risk of the type 2 diabetes mellitus patient. The protein marker combination comprises a C-C motif chemotactic factor 24, a C-C motif chemotactic factor 7, a carcino-embryonic antigen related cell adhesion molecule 6, a fiber gelling protein 1, a follistatin, a polypeptide N-acetylgalactosamino transferase 5, an ADP ribosylation factor binding protein GGA1, a kallikrein 4, a nerve bundle protein, renin, a plasma protease C1 inhibitor and cardiac troponin I, the brain natriuretic peptide comprises a brain natriuretic peptide precursor, an N-terminal brain natriuretic peptide precursor, apolipoprotein C1, tetramer connexin, a Mepin A beta subunit and multi-ligand proteoglycan-4. The invention further constructs a risk score and prediction model for predicting the attack risk of the heart failure of the type 2 diabetes mellitus patient based on the protein marker.

This invention discloses a method and apparatus for solute removal in hemodialysis with precise membrane pore size control, belonging to the field of blood purification technology. The method involves introducing blood and dialysate into both sides of a dynamically controlled bilayer heterostructure dialysis membrane, collecting characteristic signals of metabolic solutes and plasma functional proteins in the blood, inputting these signals into an adaptive pore size decision model, and outputting target pore size and electric field strength parameters. A low-frequency alternating electric field drives reversible conformational changes in stimulus-responsive polymer chains within the membrane, achieving precise control of the membrane channel's effective sieving pore size, locking the pore size within a threshold range where small molecule solutes permeate while plasma functional proteins are completely retained. Combining axial gradient channels and radial charge sieving mechanisms within the membrane achieves graded and targeted solute removal. A piezoelectrically driven periodic micro-pulsating flow field removes the fouling layer from the membrane surface, improving mass transfer stability. This invention automates and precisely controls the dialysis process, improving solute removal efficiency and plasma protein protection.

The invention discloses a group of plasma protein markers and application thereof in an ovarian cancer early diagnosis kit. Uniprot codes of the markers are respectively P02042, P02741, P02776, P06727, P07451, P07738, P30043, P68871, P69905, Q13228 and Q8IUL8, and the corresponding coding genes are respectively HBD (Hepatitis B Virus), CRP (C-Reactive Protein), PF4, APOA4, CA3, BPGM (Brassica Peptide), BLVRB (Brassica Peptide), BLVRB (Brassica Peptide Virus), HBB (Hepatitis B), HBA1, SELENBP1 and CILP2. According to the invention, a mathematical model for ovarian cancer diagnosis is constructed, the AUC under a subject ROC curve in external verification reaches 0.96, and the accuracy reaches 0.89. The protein molecular marker provided by the invention has good diagnostic index characteristics, can be effectively used for early diagnosis of ovarian cancer, and has high clinical use and popularization values.

The application discloses a method for constructing a precise prediction non-small cell lung cancer meningeal metastasis risk model based on plasma proteins and application, and relates to the technical field of biological medicine. In view of the problems of NSCLC-LM late discovery and difficult diagnosis, the inventors first attempt to use Olink proteomics technology to detect specific plasma proteins of patients in a relatively non-invasive way to know whether there is a LM risk in advance, and help patients to discover and treat early. For this purpose, the inventors first collect blood samples of LM and nLM patients, then use the training set to construct a risk prediction model, and finally judge the model performance through the validation set. The results show that FGF2, CD4, IL15, CXCL12 and PDCD1LG2 5 specific proteins are involved in model construction, and the area under the curve of the cohort is above 0.8, and the sensitivity and specificity also reach a high level. The application has great significance in the field of early diagnosis and screening of NSCLC-LM.

The application belongs to the technical field of proteomics and clinical disease screening, and relates to application of a combination of plasma proteins in screening of pancreatic cancer. The application is based on mass spectrometry quantitative proteomics technology, screens and determines a marker combination composed of four plasma proteins of GCLC, ALAD, HAGH and SORD, and comprehensively analyzes relative abundance of the marker combination through a binary Logistic regression model to distinguish pancreatic cancer patients from healthy people. Experimental results show that the protein combination has high sensitivity, specificity and area under curve (AUC) in a screening set and an independent verification set, and has good stability and repeatability. The method has the advantages of non-invasiveness, feasible operation and applicability to population screening by taking plasma as a detection sample, and can provide a new technical means for early screening of pancreatic cancer.

This invention discloses a method and device for predicting disease risk based on plasma proteomics and waist circumference, belonging to the field of medical data processing. Utilizing 2,920 plasma proteins from 52,879 participants in the UK Biobank, this invention constructs a proteomics-based waist circumference proWC score using LASSO regression, and derives the protein-anthropometric difference index proWCΔ to quantify the difference between proteomics-based waist circumference and measured waist circumference. Based on the proWC score and proWCΔ, disease risk association analysis, mortality prediction, causal mediation analysis, and dietary association analysis were conducted across 14 organ systems, demonstrating that proWC has superior clinical predictive value compared to waist circumference alone. Furthermore, based on proWC, a hidden high-risk subgroup was identified—patients with normal measured waist circumference but a near-overtly obese risk of diabetes-related death. By constructing proWCΔ and proWC, this invention elevates the assessment of central obesity from morphological measurements to the molecular level, providing a new molecular framework for precise risk stratification of central obesity.

Provided herein are minimally invasive compositions, methods, systems, kits and uses for biomarkers derived from the plasma proteome that identify, predict, and monitor organ health, aging, dysfunction and disease in humans. Said methods comprise a) obtaining a sample from said subject; b) measuring the concentrations of two or more proteins from said organ in said sample from said subject wherein said concentrations of said two or more proteins provides a biological age of said organ in health and / or disease; and c) comparing said biological age of said organ to a chronological age of said subject, wherein a gap between said biological age of said organ and said chronological age of said subject identifies accelerated and slowed aging of said organ.

The present application relates to the biomedical field, and particularly to the application of protein markers in the preparation of a reagent, kit or device for predicting the onset of type 2 diabetes. The prediction model construction method is as follows: determination of the research object, detection of the plasma proteome level, initial screening of the protein by Cox survival analysis, construction of the LASSO-Cox model and determination of the final protein combination, evaluation and verification of the model prediction performance, and the final prediction model includes 23 plasma proteins. The model is based on Olink proteome data, machine learning technology and discovery-internal verification strategy, and provides a new idea for multi-period prediction of type 2 diabetes, and has important significance for early screening and precise prevention and control of type 2 diabetes.

The present invention is directed to the bifunctional compounds and the use of such bifunctional compounds to lower plasma levels of extracellular target molecules by lysosomal degradation. Such bifunctional compounds have a cell surface receptor ligand covalently linked to a ligand that is capable of binding to an extracellular target molecule (such as a ligand for a growth factor, a cytokine, a chemokine, a hormone, a neurotransmitter, a capsid, a soluble receptor, an extracellular secreted protein, an antibody, a lipoprotein, an exosome, a virus, a cell, or a plasma membrane protein), where the cell surface receptor is associated with receptor mediated endocytosis, including asialoglycoprotein receptor (ASGPR) mediated lysosomal degradation and mannose-6-phosphate (M6PR) mediated lysosomal degradation. Pharmaceutical compositions comprising such bifunctional compounds and methods of treating a disease or disorder mediated by an extracellular molecule using such bifunctional compounds are also provided herein.

The invention discloses a plasma protein separation method, and belongs to the technical field of biological medicine. The method adopts a semi-permeable membrane to separate protein, and comprises the following steps: pumping deep filtrate into an ultrafiltration tank, and starting an ultrafilter to concentrate until the protein content reaches 50g / L or above; carrying out dialysis treatment on the concentrated solution by using water for injection, and continuously concentrating the dialyzed filtrate; flushing the ultrafilter with water for injection, merging the flushing fluid into the product, and adjusting the protein content to 40-80g / L; adjusting the pH value of the primary ultrafiltration concentrated solution by using a solution; and loading the adjusted concentrated solution to perform chromatography treatment, and collecting the flow-through liquid to perform subsequent chromatography purification. According to the method, a 50KD ultrafilter is adopted, the water temperature is 2-8 DEG C during dialysis, 4-time volume dialysis is performed, the pH value is adjusted to 6.8-7.2, the process is simple, the separation efficiency is high, and the purity and yield of plasma protein can be effectively improved.

Provided herein are minimally invasive compositions, methods, systems, kits and uses for biomarkers derived from the plasma proteome that identify, predict, and monitor organ health, aging, dysfunction and disease in humans.

The embodiment of the application belongs to the technical field of medical apparatuses, and particularly relates to a plasma separation machine. The embodiment of the application aims to solve the problem that the plasma separated by the related plasma separation machine is prone to denaturation. The plasma separation machine comprises a box body, a centrifugal machine, a plasma output assembly and a cooling device, the centrifugal machine, the plasma output assembly and the cooling device are all arranged in the box body, the plasma output assembly comprises a plasma tube and a plasma bag, the centrifugal machine has a liquid inlet end and a liquid outlet end, the liquid inlet end is configured to receive blood from a human body, the liquid outlet end is communicated with the plasma bag through the plasma tube, and the cooling device is configured to cool the plasma in at least one of the plasma bag and the plasma tube. Through the above arrangement, the cooling device cools the plasma in the plasma bag and / or the plasma tube, so as to reduce the temperature of the plasma in the plasma tube and the plasma bag, thereby preventing the plasma protein from denaturation and the coagulation factor from losing activity, and improving the quality of the plasma in the plasma bag.

The application belongs to the field of centrifugal separation devices, and provides a centrifugal separation device for extracting plasma protein, which comprises a centrifugal cylinder and further comprises a mechanism box, a fixing seat arranged at the bottom of the mechanism box, a rotating sleeve rotatably connected to the mechanism box, the centrifugal cylinder fixedly connected to the rotating sleeve, a plurality of suction cups connected to the fixing seat, and a driving mechanism arranged in the mechanism box; a plurality of positioning sleeves are annularly arranged around the rotating center of the rotating sleeve in the centrifugal cylinder, a supporting mechanism is arranged in the positioning sleeve, and the centrifugal cylinder is slidably connected to a limiting mechanism. When the air pressure in the positioning sleeve containing test tubes decreases, the rubber sleeve expands towards the inside of the positioning sleeve under the action of air pressure, so that the rubber sleeve is attached to the side wall of the test tube, thereby increasing the horizontal stability of the test tube, and the problem of poor stability when detecting raw plasma of blood products is solved.

This invention discloses a plasma protein as a biomarker for diagnosing STEMI complicated with hypertension and its application. The characteristic is that the plasma protein biomarker is CA1, which can be used in the preparation of products for diagnosing STEMI complicated with hypertension. The advantage is that STEMI complicated with hypertension can be diagnosed at an early stage by measuring the plasma protein biomarker, providing an effective tool for the diagnosis of STEMI complicated with hypertension, with high detection efficiency and strong targeting.

The application discloses a kind of innovative blood product processing and subpackaging method in the technical field of medical devices, step 1: blood raw materials are centrifuged and separated by processing device, so that plasma and blood cells are separated;Step 2: add low-temperature ethanol to the plasma to precipitate, extract plasma protein in the plasma;Step 3: select a plurality of pore sizes corresponding to plasma protein and blood cells Sterile filter membrane, terminal filtration is carried out to plasma protein and blood cells using sterile filter membrane, and plasma protein and blood cells after filtration are subpackaged, to obtain the blood product, to solve the existing problems in the prior art to a certain extent The fixed position of the discharge port is set, and in actual use, due to the fact that the number of various types of blood cells in blood is mostly different, the fixed position of the discharge port can cause the mixed target blood cells and the upper or lower blood cells, affecting the quality of subsequent finished products.

The invention provides a combined marker combination as well as a detection method and a kit thereof. The combined marker combination comprises a plasma protein marker and a blood metabolism marker, the plasma protein marker comprises an adaptor protein PH-containing structural domain, enolase 3, a proline 4-hydroxylase alpha1 chain and ethanol dehydrogenase 1C, and the adaptor protein comprises an adaptor protein PH-containing structural domain, a proline 4-hydroxylase alpha1 chain and a proline 4-hydroxylase alpha2 chain. The blood metabolism marker is prepared from diosgenin, eicosapentaenoic acid, folinic acid, hydroxyprogesterone hexanoate, testosterone, perfluorooctane sulfonic acid, prasterone sulfate, androstane dienone, long pine needle ketone and 1-(22 carbon 4 enoyl) lysophosphatidylcholine. Through cooperative detection of protein-metabolism markers and combined application of a machine learning model, accurate prediction of the age-related disease risk is achieved, the cognitive decline risk can be pre-judged in advance, meanwhile, efficient synchronous detection of multiple markers is achieved by means of a liquid chromatography-tandem mass spectrometry synchronous detection technology, the sample dosage is small, the detection process is standardized, and the detection efficiency is high. The large-scale queue research requirement is met, and multi-center clinical application and popularization are facilitated.